癫痫手术后根据组织病理诊断的发作结局与抗癫痫药物使用:回顾性多中心队列研究
该回顾性多中心队列研究纳入欧洲18国37个中心2000至2012年间接受癫痫手术的9147例患者,分析组织病理诊断与术后1、2、5年无致残性发作(Engel 1级)及无药生存的关联。低级别癫痫相关神经上皮肿瘤、血管畸形和海马硬化术后2年Engel 1级比例最高,局灶皮质发育不良I型或轻度皮质发育畸形、其他皮质发育畸形及无病理病变者最差;儿童更常无药,颞叶手术结局最佳,癫痫病程越长结局越差。
要点
- 低级别癫痫相关神经上皮肿瘤、血管畸形和海马硬化术后2年无致残性发作比例最高。
- 局灶皮质发育不良I型或轻度皮质发育畸形、其他皮质发育畸形及无病理病变者结局最差。
- 儿童更常无药,颞叶手术结局最佳,癫痫病程越长结局越差。
核心结论
- 组织病理诊断、手术年龄和癫痫病程是癫痫手术结局的重要预后因素。
- 对所有推测为病变性难治性局灶性癫痫患者,应考虑手术评估。
研究设计与样本
- 回顾性、多中心、纵向队列研究,纳入欧洲癫痫脑库联盟18国37个中心2000年1月1日至2012年12月31日接受癫痫手术且术后有组织病理诊断的各年龄段患者。
- 采用随机效应多变量逻辑回归分析组织病理、癫痫病程和手术年龄与主要结局的关联。
主要发现
- 同时达到Engel 1级且无药的比例从1年时的0-14%增至5年时的14-51%。
- 儿童更常无药;颞叶手术发作结局最佳;癫痫病程越长,获得良好发作结局和无药的机会越低。
- 病程的上述影响见于所有病变,但海马硬化除外。
关键数值与推荐
- 主要结局为术后1、2、5年无致残性发作(Engel 1级)和无药。
- 按11类主要组织病理诊断报告Engel 1级和无药的比例。
临床怎么用
- 术前应结合组织病理诊断、手术年龄和癫痫病程进行预后咨询和手术决策。
- 对推测为病变性难治性局灶性癫痫患者,均应考虑手术评估。
- 颞叶手术和儿童患者可能更有利于发作结局和无药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery is a widely accepted treatment option for drug-resistant focal epilepsy. A detailed analysis of longitudinal postoperative seizure outcomes and use of antiepileptic drugs for different brain lesions causing epilepsy is not available. We aimed to analyse the association between histopathology and seizure outcome and drug freedom up to 5 years after epilepsy surgery, to improve presurgical decision making and counselling. METHODS: In this retrospective, multicentre, longitudinal, cohort study, patients who had epilepsy surgery between Jan 1, 2000, and Dec 31, 2012, at 37 collaborating tertiary referral centres across 18 European countries of the European Epilepsy Brain Bank consortium were assessed. We included patients of all ages with histopathology available after epilepsy surgery. Histopathological diagnoses and a minimal dataset of clinical variables were collected from existing local databases and patient records. The primary outcomes were freedom from disabling seizures (Engel class 1) and drug freedom at 1, 2, and 5 years after surgery. Proportions of individuals who were Engel class 1 and drug-free were reported for the 11 main categories of histopathological diagnosis. We analysed the association between histopathology, duration of epilepsy, and age at surgery, and the primary outcomes using random effects multivariable logistic regression to control for confounding. FINDINGS: 9147 patients were included, of whom seizure outcomes were available for 8191 (89·5%) participants at 2 years, and for 5577 (61·0%) at 5 years. The diagnoses of low-grade epilepsy associated neuroepithelial tumour (LEAT), vascular malformation, and hippocampal sclerosis had the best seizure outcome at 2 years after surgery, with 77·5% (1027 of 1325) of patients free from disabling seizures for LEAT, 74·0% (328 of 443) for vascular malformation, and 71·5% (2108 of 2948) for hippocampal sclerosis. The worst seizure outcomes at 2 years were seen for patients with focal cortical dysplasia type I or mild malformation of cortical development (50·0%, 213 of 426 free from disabling seizures), those with malformation of cortical development-other (52·3%, 212 of 405 free from disabling seizures), and for those with no histopathological lesion (53·5%, 396 of 740 free from disabling seizures). The proportion of patients being both Engel class 1 and drug-free was 0-14% at 1 year and increased to 14-51% at 5 years. Children were more often drug-free; temporal lobe surgeries had the best seizure outcomes; and a longer duration of epilepsy was associated with reduced chance of favourable seizure outcomes and drug freedom. This effect of duration was evident for all lesions, except for hippocampal sclerosis. INTERPRETATION: Histopathological diagnosis, age at surgery, and duration of epilepsy are important prognostic factors for outcomes of epilepsy surgery. In every patient with refractory focal epilepsy presumed to be lesional, evaluation for surgery should be considered. FUNDING: None.
引用
- Lamberink HJ, Otte WM, Blümcke I, et al. Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study. Lancet Neurol. 2020. PMID: 32822635. doi:10.1016/S1474-4422(20)30220-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。